Available on demand: Why the success of your HTA will rely on real world evidence

This webinar is the first in a series of webinars focused on the topic: Unlocking the value; the economic equation. It is also part of the IMS Health Practical Insights series.

While the randomised clinical trial remains the gold standard, the feasibility of large-scale trials within a pipeline that is ever more focused on niche and personalised medicines is decreasing – particularly in the fields of rare diseases and oncology. Within the changing landscape of drug development, payers continue to demand robust evidence to assess the value and effectiveness of innovative treatments for both smaller patient populations and increasingly expensive medicines. Addressing this tension is where real world evidence can step in.

Topics covered include:

• The HTA landscape – the challenges of assessing rare diseases and cancer medicines

• Recent case studies – successes and failures

• Learnings from best practice in global markets

• How to assess RWE in an HTA – an academic perspective

• Wrap up: How RWE can assist with HTA

The live broadcast took place on Thursday 11 February 2016 at 14.00 GMT, 15.00 CET (09.00 EST). To view the on demand version, please click here or on the webinar widget below.

Participant line up

Adam Lloyd, Senior Principal, Health Economics and Outcomes Research, IMS Health

Adam graduated from the University of Oxford with an MPhil in economics. He has 20 years' experience conducting economic evaluations of health technologies in consulting and the pharmaceutical industry. Adam has extensive experience of decision-analytic and Markov modelling, and of preparing and defending submissions to HTA bodies including NICE and the SMC. His interests include methods of adapting economic models to heterogeneous customer needs in multi-country analyses, and the design of evidence collection strategies to meet the needs of HTA decision makers. He is currently head of health economics at the London office of IMS.

Eric Yu, Principal, Real World Evidence Solutions, IMS Health

Eric leads projects which leverage both IMS and non-IMS real world data sources for the purposes of evidence generation within industry. He has worked extensively across healthcare in various capacities, starting as a clinical pharmacist and senior manager at a private healthcare provider and latterly as a management consultant. As a consultant within healthcare, he has advised the NHS on diverse matters from financial savings, business cases, organisational turnaround, econometric models, contracting frameworks and negotiations. Immediately prior to joining IMS he was a strategy consultant for a clinical system vendor driving health system efficiencies and health outcomes at a population level through effective leverage of data. Academically

He has an MSc in International Health Management from Imperial College London, an MPharm in Pharmacy from University College London and clinical qualifications from Queens University Belfast. He is licensed by the General Pharmaceutical Council, a member of the Royal Pharmaceutical Society and an associate member of the Royal Society of Chemistry. Currently, he is pursuing an LLM in Law from the University of London with a focus on international development, intellectual property rights and health as a human rights.

Rita Faria, University of York
Rita Faria is a research fellow at the Centre for Health Economics, University of York. Rita's research interests are focused on the methods for the economic evaluation in health and social care. Some of her recent work includes single and multiple technology appraisals for NICE and economic evaluations of both health and social care interventions. She has recently co-authored the NICE Decision Support Unit technical support document on the use of non-randomised data.